2022 World Conference on Lung Cancer (ePosters)-EP11.01-011. Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma

EP11.01-011. Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma

Back to course

Pdf Summary

Liquid biopsy, a method of analyzing cell-free DNA (cfDNA), has emerged as a promising less invasive alternative to tissue genotyping for detecting EGFR resistance mutations in non-small cell lung carcinoma (NSCLC) patients. However, its potential for early detection of EGFR mutation in treatment-naïve patients is less explored. This study aimed to determine the use of cfDNA for early detection of EGFR mutation in NSCLC patients.<br /><br />Peripheral blood samples were collected from 100 lung cancer patients, and out of eligible 55 patients, their matched plasma cfDNA was tested for EGFR mutation detection at the time of diagnosis. The study found that liquid biopsy for EGFR mutation detection in treatment-naïve patients had a shorter turnaround time compared to standard tissue biopsy, reducing potential delays in initiating EGFR TKI therapy.<br /><br />Liquid biopsy also proved effective in cases where tissue biopsy was unfeasible or inadequate, revolutionizing the care of NSCLC patients. The study achieved high sensitivity from both ARMS-PCR and ddPCR methods, surpassing the more complex Next Generation Sequencing technology.<br /><br />The benefits of liquid biopsy for EGFR mutation analysis in NSCLC patients have been acknowledged, as it improves the time to optimal therapy decision-making and allows for early initiation of targeted therapies. The study also referenced previous research that compared the sensitivity of tissue biopsy and liquid biopsy, highlighting the superiority of liquid biopsy in terms of cost and turnaround time.<br /><br />In conclusion, liquid biopsy using cfDNA is a valuable tool for early detection of EGFR mutation in NSCLC patients. It offers a less invasive and efficient method for assessing EGFR status, especially in treatment-naïve patients and those with unfeasible tissue biopsy. Further research and validation are needed to integrate liquid biopsy into routine clinical practice for NSCLC patients.

Asset Subtitle

Amber Rathor

Meta Tag

Speaker Amber Rathor

Topic Pathology - Genomics & Analytics

Keywords

Liquid biopsy

cfDNA

EGFR resistance mutations

NSCLC patients

early detection

treatment-naïve patients

turnaround time

EGFR TKI therapy

tissue biopsy

targeted therapies